>世界の分子ポイントオブケア検査（NAAT を使用）市場、製品別（機器および消耗品と試薬）、適応症別（呼吸器感染症検査、性感染症（STI）検査、胃腸管感染症検査、その他）、エンドユーザー別（研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他）、検査モード別（処方箋に基づく検査および OTC 検査）、流通チャネル別（病院薬局、小売薬局、オンライン薬局）– 2028 年までの業界動向と予測。
分子ポイントオブケア検査（NAAT を使用）市場分析と洞察
世界の分子ポイントオブケア検査（NAAT を使用）市場は、医療施設やインフラの改善、病院、研究所、診療所での終末期検査の導入により、市場の成長を牽引する可能性があり、成長すると予想されています。分子ポイントオブケア検査（NAAT を使用）市場の発展を促進すると予想されるその他の要因には、感染症の蔓延の増加が含まれます。
熟練した専門家の不足やカスタマイズされた分子ポイントオブケア検査（NAAT を使用）の高コストなどの他の要因は、世界の分子エンドオブケア検査（NAAT を使用）市場の成長を妨げています。一方、医療費の増加と病院が発達した新興国は、世界の分子ポイントオブケア検査（NAAT を使用）市場を成長させる機会として機能します。
Data Bridge Market Research は、世界の分子ポイントオブケア検査 (NAAT を使用) 市場は 2021 年から 2028 年にかけて 10.8% の CAGR で成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2021年から2028年 |
|
基準年 |
2020 |
|
歴史的な年 |
2019 |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
製品別（器具、消耗品、試薬）、適応症別（呼吸器感染症検査、性感染症（STI）検査、消化管感染症検査、その他）、エンドユーザー別（研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他）、検査方法別（処方箋に基づく検査およびOTC検査）、流通チャネル別（病院薬局、小売薬局、オンライン薬局） |
|
対象国 |
北米（米国、カナダ）、ヨーロッパ（英国、ドイツ、フランス、スペイン、イタリア、その他のヨーロッパ）、南アジア（パキスタン、バングラデシュ、インド、その他の南アジア）、東南アジア（シンガポール、マレーシア、ベトナム、インドネシア、タイ、フィリピン、その他の東南アジア）、中東（サウジアラビア、UAE、エジプト、イスラエル、その他の中東）、アフリカ（南アフリカ、ケニア、ナイジェリア、その他のアフリカ） |
|
対象となる市場プレーヤー |
SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Danaher、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Sysmex Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc.、Grifols SA、Wondfo、Oxford Nanopore Diagnostic、PerkinElmer Inc.、およびCo-Diagnostic、 |
世界の分子ポイントオブケア検査（NAAT 使用）市場の市場定義
POCT は、患者の近くで実施できる検査として特徴付けられ、結果とモニタリングを含め、医療上の決定を即座に行うことができます。現在臨床使用されている POCT デバイスは、ここでは第 2 世代デバイスと定義される核酸増幅技術 (NAAT) に基づいています。これらのプラットフォームは、第 1 世代 POCT と比較して、一般的に感度が向上しており、通常は 60 ～ 90% 向上しており、設置面積が約 30cm x 30cm のポータブル機器が必要です。これらの機器は基本的に、 NAAT 技術を使用してHIV、HPV、呼吸器疾患などのさまざまな疾患を分子レベルで検出するために使用されます。NAAT は、病原体の DNA または RNA を検出することで病原体を特定できる核酸増幅技術です。
世界的なパンデミックの中で、NAATの感度とPOCTアッセイの使いやすさを相乗的に利用しようとする試みとして、COVID-19のスクリーニングと診断を迅速化するために小型化されたNAATベースのPOCTデバイスとアッセイが考案され、これも市場の成長を後押ししました。
世界の分子ポイントオブケア検査（NAAT 使用）市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 慢性疾患の罹患率の増加
健康の衰えは加齢とともに始まるというのはよく知られた事実です。慢性疾患の割合が時間とともに増加するにつれて、疾患の割合に関連する要因も増加します。肥満/太りすぎの人口が多いことも、世界中のさまざまな地域で慢性疾患の有病率を増加させています。HPV、STI、TBなどの慢性疾患の増加により、人々はNAATベースのポイントオブケアと検査用製品を選択するようになりました。したがって、これは今後数年間で世界の分子ポイントオブケア検査（NAATを使用）市場の成長を促進するでしょう。
- 診断受診率の向上
がん、貧血、2 型糖尿病などの慢性疾患の診断成功率の増加に伴い、改善された医療専門家は、地域の診断率の向上を考慮して、検査を実施するための専門家向けの定期的なトレーニング セッションを提供しています。疾患の負担が増加するにつれて、診断率も増加しています。診断の進歩により、診断を受ける人の割合も増加しています。
- 在宅ケア検査の好感度が上昇
在宅医療の好みにより、適切な場所と時間に臨床情報を入手できるようになります。また、品質を確保することで、間違いを減らし、安全性を高めることにも役立ちます。また、医療上の緊急事態が発生した場合、高齢者の助けにもなります。ポイントオブケア検査の利点に対処するために、医療分野では多くの戦略的変更が行われてきました。世界保健機関 (WHO) によると、65 歳以上の人口は 2010 年の推定 5 億 2,400 万人から 2050 年にはおよそ 15 億人に増加すると予想されており、その増加の大部分は先進国で発生します。
機会
- 市場参加者による戦略的取り組み
慢性および非慢性疾患の負担が世界的に増加し、アフリカとアジアの高齢者人口も増加しているため、より有効で時間のかからない分子ポイントオブケア検査用の新しいキットとソリューションの開発に対する需要が高まっています。この地域で診断とスクリーニングを提供するために、市場のプレーヤーは、キットと機器を通じて世界中の人々に質の高いケアを提供するためのパートナーシップと契約を結んでいます。
- 医療費の増加
医療費とインフラストラクチャの増加により、患者は手間をかけずに高度な治療を受け、より適切な診断、処置、治療を受け、回復を早めることができます。ポイントオブケア検査機器は、POC ソフトウェアとソリューションを使用してさまざまな病気を検出し、治療計画をサポートするのに役立ちます。医療費は、自己負担（治療費を負担する人々）、政府支出、健康保険や非政府組織の活動などの資金源から構成されます。
制約/課題
- 製品の高コスト
ポイントオブケア検査製品の開発プロセスには、かなりのコストがかかります。コンセプトを確定させる必要があるため、材料を調達する必要があり、リードタイムを考慮することが不可欠です。さらに、デバイス設計が完全に成熟するまでに十分な時間が必要であり、市場に投入して使用できるようになるまで時間がかかるため、プロセスには時間がかかります。
- 研究所から得られた試験結果との整合性の欠如
臨床検査基準の結果と比較すると、NAAT 検査の結果は異なります。臨床検査はより高度で、臨床検査のプロセス、プロトコル、科学に従い、効果を正確に分析、検証、文書化するために必要なテクノロジーと完全に統合されています。ただし、POCT/NAAT は正確な結果が不足していることは間違いありません。分子 POCT は標準化を完了できず、その他の重要な基準は標準化とさまざまな必須基準を達成できません。これは、世界の分子ポイント オブ ケア検査市場にとって大きな課題です。PoC テストでは、誤った結果が提供される場合があり、テスト結果にばらつきが生じます。
COVID-19後の世界の分子ポイントオブケア検査（NAATを使用）市場への影響
COVID-19は、分子ポイントオブケア検査（NAATを使用）市場に大きな影響を与えました。COVID-19は、オンライン販売の進歩と製品の技術的進歩により、分子ポイントオブケア検査（NAATを使用）製品の価格と需要に高いレベルでプラスの影響を与えました。COVID-19パンデミックの発生は、特にさまざまな病院で分子ポイントオブケア検査（NAATを使用）に対する高い需要により、市場の成長にプラスの影響を与えました。COVID-19症例の急増が依然として続いているため、ほとんどの病院では現在、COVID-19治療が優先されており、分子ポイントオブケア検査（NAATを使用）の使用も増加しています。さらに、多くの国際政府や医療機関は、重要な症例での優先度が高いため、これらの製品の供給を支援してきました。
最近の動向
- 2021年11月、F.ホフマン・ラ・ロシュ社は、ロシュがダウ・ジョーンズ・サステナビリティ・インデックスにおいて13年連続で最も持続可能なヘルスケア企業トップ3にランクされたと発表しました。これにより、予測期間中の事業遂行能力と事業拡大が増加しました。
- 2021年10月、サーモフィッシャーサイエンティフィックコーポレーションは、TaqMan COVId-19テストSARS-COV分子アッセイのFDA承認を取得しました。これにより、同社の製品ポートフォリオが増加し、予測期間中の同社の収益に貢献しました。
世界の分子ポイントオブケア検査（NAAT 使用）市場の範囲
世界の分子ポイントオブケア検査（NAAT 使用）市場は、製品、適応症、エンドユーザー、検査モード、流通チャネルに基づいて 5 つの主要なセグメントに分類されます。これらのセグメントの成長は、業界の市場成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
製品
- 楽器
- 消耗品および試薬
製品に基づいて、世界の分子ポイントオブケア検査（NAAT を使用）市場は、機器と消耗品および試薬に分類されます。
表示
- 性感染症（STI）検査
- 呼吸器感染症検査
- 消化管感染症検査
- その他
適応症に基づいて、世界の分子ポイントオブケア検査（NAAT を使用）市場は、性感染症（STI）検査、呼吸器感染症検査、胃腸管感染症検査、その他に分類されます。
エンドユーザー
- 研究所
- 病院
- クリニック
- 外来センター
- ホームケア
- 介護施設
- その他
エンドユーザーに基づいて、世界の分子ポイントオブケア検査（NAAT を使用）市場は、研究所、病院、診療所、外来センター、在宅ケア、介護施設、その他に分類されます。
テストのモード
- 処方箋に基づく検査
- OTC検査
検査方法に基づいて、世界の分子ポイントオブケア検査（NAAT を使用）市場は、処方箋に基づく検査と OTC 検査に分類されます。
流通チャネル
- 病院薬局
- 小売薬局
- オンライン薬局
流通チャネルに基づいて、世界の分子ポイントオブケア検査（NAAT を使用）市場は、病院薬局、小売薬局、オンライン薬局に分類されます。
世界の分子ポイントオブケア検査（NAAT 使用）市場の地域分析/洞察
世界の分子ポイントオブケア検査（NAAT を使用）市場は、製品、適応症、エンドユーザー、検査モード、流通チャネルに基づいて 5 つの主要なセグメントに分類されます。
世界の分子ポイントオブケア検査（NAAT を使用）市場は、北米（米国、カナダ）、ヨーロッパ（英国、ドイツ、フランス、スペイン、イタリア、その他のヨーロッパ）、南アジア（パキスタン、バングラデシュ、インド、その他の南アジア）、東南アジア（シンガポール、マレーシア、ベトナム、インドネシア、タイ、フィリピン、その他の東南アジア）、中東（サウジアラビア、UAE、エジプト、イスラエル、その他の中東）、アフリカ（南アフリカ、ケニア、ナイジェリア、その他のアフリカ）の国に分類されています。
北米は、市場シェアと市場収益の点で約 12.1% の CAGR で世界の分子ポイント オブ ケア検査 (NAAT を使用) 市場を支配しています。予測期間中、北米はその優位性を維持し続けるでしょう。これは、感染症や慢性疾患の蔓延の増加と、病院でのポイント オブ ケア検査の導入によるものです。
競争環境と世界的な分子ポイントオブケア検査（NAAT を使用）市場シェア分析
世界的な分子ポイントオブケア検査 (NAAT を使用) 市場の競争状況は、競合他社に関する詳細を提供します。含まれるコンポーネントは、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、会社の強みと弱み、製品の発売、規制ガイドライン、ブランド分析、製品の承認、製品のペイロード、アプリケーションの優位性、技術ライフライン曲線です。提供されている上記のデータ ポイントは、世界的な分子トピックオブケア検査 (NAAT を使用) 市場への会社の重点にのみ関連しています。
Danaher は、この市場で支配的なプレーヤーです。世界の分子ポイント オブ ケア検査 (NAAT を使用) 市場で活動している他の主要プレーヤーには、SD Biosensor, Inc.、Abbott、F.Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc、binx Health, Inc.、Lucira、Meridian Bioscience、Quantumdx Group Ltd.、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Sysmex Corporation、Bio-Rad Laboratories, Inc.、Sekisui Diagnostic、Randox Laboratories Ltd.、GenMark Diagnostics、Seegene Inc.、Grifols SA、Wondfo、Oxford Nanopore Diagnostic、PerkinElmer Inc.、Co-Diagnostic などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES
4.3.1 CEPHEID
4.3.2 THERMO FISHER SCIENTIFIC INC.
4.3.3 HOLOGIC, INC.
4.3.4 BD
4.3.5 F. HOFFMANN-LA ROCHE LTD
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY
4.5 DISTRIBUTORS
4.5.1 NORTH AMERICA
4.5.2 EUROPE
4.5.3 SOUTH ASIA
4.5.4 SOUTH EAST ASIA
4.5.5 MIDDLE EAST
4.5.6 AFRICA
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING
6.2 RESTRAINTS
6.2.1 PRODUCT RECALLS
6.2.2 HIGH COSTS OF PRODUCTS
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING HEALTHCARE EXPENDITURE
6.3.3 PANDEMIC OUTBREAK OF COVID-19
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS
6.4 CHALLENGES
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES
6.4.2 LACK OF ACCESSIBILITY
7 IMPACT OF COVID-19 ON THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19
7.5 CONCLUSION:
8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & REAGENTS
8.3 INSTRUMENTS
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)
9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS TESTING
9.2.1 COVID-19
9.2.2 FLU B
9.2.3 FLU A
9.2.4 RSV
9.2.5 TUBERCULOSIS
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)
9.2.7 OTHERS
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING
9.3.1 TV
9.3.2 CT
9.3.3 NG
9.3.4 HPV
9.3.5 HSV
9.3.6 MG
9.3.7 UU
9.3.8 MH
9.3.9 OTHERS
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING
9.4.1 GROUP B STREPTOCOCCUS
9.4.2 SHIGA TOXIN
9.4.3 H. PYLORI
9.5 OTHERS
10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER
10.1 OVERVIEW
10.2 LABORATORIES
10.2.1 POLYMERASE CHAIN REACTION
10.2.2 ISOTHERMAL AMPLIFICATION
10.3 HOSPITAL
10.3.1 POLYMERASE CHAIN REACTION
10.3.2 ISOTHERMAL AMPLIFICATION
10.4 CLINICS
10.4.1 POLYMERASE CHAIN REACTION
10.4.2 ISOTHERMAL AMPLIFICATION
10.5 AMBULATORY CENTER
10.5.1 POLYMERASE CHAIN REACTION
10.5.2 ISOTHERMAL AMPLIFICATION
10.6 HOMECARE
10.6.1 POLYMERASE CHAIN REACTION
10.6.2 ISOTHERMAL AMPLIFICATION
10.7 ASSISTED LIVING FACILITIES
10.7.1 POLYMERASE CHAIN REACTION
10.7.2 ISOTHERMAL AMPLIFICATION
10.8 OTHERS
11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING
11.1 OVERVIEW
11.2 PRESCRIPTION-BASED TESTING
11.3 OTC TESTING
12 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION
13.1 OVERVIEW
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.3 EUROPE
13.3.1 U.K.
13.3.2 GERMANY
13.3.3 ITALY
13.3.4 FRANCE
13.3.5 SPAIN
13.3.6 REST OF EUROPE
13.4 SOUTH ASIA
13.4.1 INDIA
13.4.2 PAKISTAN
13.4.3 BANGLADESH
13.4.4 REST OF SOUTH ASIA
13.5 SOUTH EAST ASIA
13.5.1 SINGAPORE
13.5.2 VIETNAM
13.5.3 THAILAND
13.5.4 MALAYSIA
13.5.5 INDONESIA
13.5.6 PHILIPPINES
13.5.7 REST OF SOUTH EAST ASIA
13.6 MIDDLE EAST
13.6.1 SAUDI ARABIA
13.6.2 U.A.E
13.6.3 ISRAEL
13.6.4 EGYPT
13.6.5 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 SOUTH AFRICA
13.7.2 KENYA
13.7.3 NIGERIA
13.7.4 REST OF AFRICA
14 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: SOUTH ASIA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 DANAHER
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 BD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 F.HOFFMANN-LA-ROCHE LTD.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BINX HEALTH, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BIOMERIEUX SA
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 CO-DIAGNOSTICS, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 GENMARK DIAGNOSTICS, INC
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.1 GRIFOLS, S.A.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 LUCIRA HEALTH INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 MERIDIAN BIOSCIENCE
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 QUANTUMDX GROUP LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 QUIDEL CORPORATION
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 SD BIOSENSOR, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.18 WONDFO
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)
TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)
TABLE 7 DISTRIBUTORS ACROSS NORTH AMERICA
TABLE 8 DISTRIBUTORS ACROSS EUROPE
TABLE 9 DISTRIBUTORS ACROSS SOUTH ASIA
TABLE 10 DISTRIBUTORS ACROSS SOUTH EAST ASIA
TABLE 11 DISTRIBUTORS ACROSS MIDDLE EAST
TABLE 12 DISTRIBUTORS ACROSS AFRICA
TABLE 13 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 14 GLOBAL CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 GLOBAL INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 17 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 18 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 20 GLOBAL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 GLOBAL SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 22 GLOBAL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 GLOBAL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 24 GLOBAL OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 26 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 GLOBAL LABOROTORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 28 GLOBAL HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 GLOBAL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 30 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 GLOBAL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 32 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 GLOBAL AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 34 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 GLOBAL HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 36 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 38 GLOBAL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 40 GLOBAL PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 41 GLOBAL OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 GLOBAL HOSPITAL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 GLOBAL RETAIL PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 GLOBAL ONLINE PHARMACY IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 U.S. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 65 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 66 U.S. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 67 U.S. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 68 U.S. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 69 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 U.S. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 71 U.S. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 72 U.S. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 77 U.S. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 78 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 79 CANADA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 81 CANADA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 82 CANADA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 83 CANADA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 84 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 85 CANADA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 86 CANADA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 87 CANADA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 88 CANADA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 89 CANADA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 90 CANADA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 92 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 94 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 95 EUROPE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 97 EUROPE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 98 EUROPE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 99 EUROPE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 100 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 EUROPE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 102 EUROPE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 103 EUROPE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 104 EUROPE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 105 EUROPE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 106 EUROPE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 107 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 108 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 110 U.K. INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 111 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 112 U.K. RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 113 U.K. SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 114 U.K. GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 115 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 U.K. LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 117 U.K. HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 118 U.K. CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 119 U.K. AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 120 U.K. HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 121 U.K. ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 122 U.K. MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 123 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 GERMANY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 127 GERMANY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 GERMANY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 129 GERMANY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 130 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 131 GERMANY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 GERMANY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 GERMANY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 134 GERMANY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 135 GERMANY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 136 GERMANY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 137 GERMANY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 138 CANADA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 ITALY INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 142 ITALY RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 143 ITALY SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 144 ITALY GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 145 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 146 ITALY LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 ITALY HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 ITALY CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 ITALY AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 ITALY HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 ITALY ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 152 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 153 ITALY MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 155 FRANCE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 157 FRANCE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 158 FRANCE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 159 FRANCE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 160 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 161 FRANCE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 162 FRANCE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 163 FRANCE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 164 FRANCE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 165 FRANCE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 166 FRANCE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 167 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 168 FRANCE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 170 SPAIN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 171 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 172 SPAIN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 173 SPAIN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 174 SPAIN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 175 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 176 SPAIN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 177 SPAIN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 178 SPAIN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 179 SPAIN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 180 SPAIN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 181 SPAIN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 182 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 183 SPAIN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 185 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 186 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 187 SOUTH ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 188 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 189 SOUTH ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 191 SOUTH ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 192 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 193 SOUTH ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 194 SOUTH ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 195 SOUTH ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 196 SOUTH ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 197 SOUTH ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 198 SOUTH ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 199 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 200 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 201 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 202 INDIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 203 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 204 INDIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 205 INDIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 206 INDIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 207 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 208 INDIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 209 INDIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 210 INDIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 211 INDIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 212 INDIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 213 INDIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 214 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 215 INDIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 216 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 217 PAKISTAN INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 218 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 219 PAKISTAN RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 220 PAKISTAN SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 221 PAKISTAN GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 222 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 223 PAKISTAN LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 224 PAKISTAN HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 225 PAKISTAN CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 226 PAKISTAN AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 227 PAKISTAN HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 228 PAKISTAN ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 229 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 230 PAKISTAN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 231 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 232 BANGLADESH INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 233 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 234 BANGLADESH RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 235 BANGLADESH SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 236 BANGLADESH GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 237 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 238 BANGLADESH LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 239 BANGLADESH HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 240 BANGLADESH CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 241 BANGLADESH AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 242 BANGLADESH HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 243 BANGLADESH ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 244 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 245 BANGLADESH MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 246 REST OF SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 247 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 248 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 249 SOUTH EAST ASIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 250 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 251 SOUTH EAST ASIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 252 SOUTH EAST ASIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 253 SOUTH EAST ASIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 254 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 255 SOUTH EAST ASIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 256 SOUTH EAST ASIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 257 SOUTH EAST ASIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 258 SOUTH EAST ASIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 259 SOUTH EAST ASIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 260 SOUTH EAST ASIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 261 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 262 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 263 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 264 SINGAPORE INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 265 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 266 SINGAPORE RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 267 SINGAPORE SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 268 SINGAPORE GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 269 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 270 SINGAPORE LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 271 SINGAPORE HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 272 SINGAPORE CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 273 SINGAPORE AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 274 SINGAPORE HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 275 SINGAPORE ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 276 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 277 SINGAPORE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 278 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 279 VIETNAM INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 280 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 281 VIETNAM RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 282 VIETNAM SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 283 VIETNAM GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 284 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 VIETNAM LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 286 VIETNAM HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 287 VIETNAM CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 288 VIETNAM AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 289 VIETNAM HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 290 VIETNAM ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 291 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 292 VIETNAM MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 293 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 294 THAILAND INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 295 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 296 THAILAND RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 297 THAILAND SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 298 THAILAND GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 299 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 300 THAILAND LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 301 THAILAND HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 302 THAILAND CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 303 THAILAND AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 304 THAILAND HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 305 THAILAND ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 306 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 307 THAILAND MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 308 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 309 MALAYSIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 310 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 311 MALAYSIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 312 MALAYSIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 313 MALAYSIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 314 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 315 MALAYSIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 316 MALAYSIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 317 MALAYSIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 318 MALAYSIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 319 MALAYSIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 320 MALAYSIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 321 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 322 MALAYSIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 323 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 324 INDONESIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 325 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 326 INDONESIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 327 INDONESIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 328 INDONESIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 329 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 330 INDONESIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 331 INDONESIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 332 INDONESIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 333 INDONESIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 334 INDONESIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 335 INDONESIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 336 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 337 INDONESIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 338 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 339 PHILIPPINES INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 340 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 341 PHILIPPINES RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 342 PHILIPPINES SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 343 PHILIPPINES GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 344 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 345 PHILIPPINES LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 346 PHILIPPINES HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 347 PHILIPPINES CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 348 PHILIPPINES AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 349 PHILIPPINES HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 350 PHILIPPINES ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 351 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 352 PHILIPPINES MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 353 REST OF SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 354 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 355 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 356 MIDDLE EAST INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 357 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 358 MIDDLE EAST RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 359 MIDDLE EAST SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 360 MIDDLE EAST GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 361 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 362 MIDDLE EAST LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 363 MIDDLE EAST HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 364 MIDDLE EAST CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 365 MIDDLE EAST AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 366 MIDDLE EAST HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 367 MIDDLE EAST ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 368 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 369 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 370 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 371 SAUDI ARABIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 372 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 373 SAUDI ARABIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 374 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 375 SAUDI ARABIAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 376 SAUDI ARABIAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 377 SAUDI ARABIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 378 SAUDI ARABIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 379 SAUDI ARABIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 380 SAUDI ARABIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 381 SAUDI ARABIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 382 SAUDI ARABIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 383 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 384 SAUDI ARABIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 385 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 386 U.A.E INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 387 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 388 U.A.E RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 389 U.A.E SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 390 U.A.E GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 391 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 392 U.A.E LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 393 U.A.E HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 394 U.A.E CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 395 U.A.E AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 396 U.A.E HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 397 U.A.E ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 398 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 399 U.A.E MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 400 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 401 ISRAEL INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 402 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 403 ISRAEL RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 404 ISRAEL SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 405 ISRAEL GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 406 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 407 ISRAEL LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 408 ISRAEL HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 409 ISRAEL CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 410 ISRAEL AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 411 ISRAEL HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 412 ISRAEL ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 413 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 414 ISRAEL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 415 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 416 EGYPT INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 417 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 418 EGYPT RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 419 EGYPT SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 420 EGYPT GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 421 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 422 EGYPT LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 423 EGYPT HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 424 EGYPT CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 425 EGYPT AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 426 EGYPT HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 427 EGYPT ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 428 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 429 EGYPT MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 431 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 432 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 433 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 434 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 435 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 436 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 437 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 438 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 439 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 440 AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 441 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 442 AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 443 AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 444 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 445 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 446 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 447 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 448 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 449 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 450 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 451 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 452 SOUTH AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 453 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 454 SOUTH AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 455 SOUTH AFRICA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 456 SOUTH AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 457 SOUTH AFRICA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 458 SOUTH AFRICA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 459 SOUTH AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 460 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 461 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 462 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 463 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 464 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 465 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 466 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 467 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 468 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 469 KENYA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 470 KENYA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 471 KENYA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 472 KENYA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 473 KENYA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 474 KENYA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 475 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 476 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 477 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 478 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 479 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 480 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 481 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 482 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)
TABLE 483 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 484 NIGERIA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 485 NIGERIA HOSPITALS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 486 NIGERIA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 487 NIGERIA AMBULATORY CENTERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 488 NIGERIA HOMECARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 489 NIGERIA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 490 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)
TABLE 491 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 492 REST OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
図表一覧
FIGURE 1 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 2 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING
FIGURE 8 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID
FIGURE 11 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS-SEEKING RATE ARE EXPECTED TO DRIVE THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD
FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028
FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE MOLECULAR POINT OF CARE TESTING (USING NAAT) MANUFACTURERS IN THE FORECAST PERIOD
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET
FIGURE 17 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016
FIGURE 18 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020
FIGURE 19 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 20 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 21 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 22 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020
FIGURE 23 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 24 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 25 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020
FIGURE 27 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 28 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)
FIGURE 29 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020
FIGURE 31 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)
FIGURE 32 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)
FIGURE 33 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE
FIGURE 34 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 36 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 39 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020)
FIGURE 40 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2021 & 2028)
FIGURE 41 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY REGION (2020 & 2028)
FIGURE 42 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 43 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 44 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 45 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 48 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 49 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 50 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 51 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 52 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 53 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 54 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 55 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 56 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 57 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 58 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 59 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 60 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 61 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 62 SOUTH EAST ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 63 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 64 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 65 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 66 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 67 MIDDLE EAST MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 68 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)
FIGURE 69 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)
FIGURE 70 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 71 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 72 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)
FIGURE 73 GLOBAL MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 74 NORTH AMERICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 75 EUROPE MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
FIGURE 76 SOUTH ASIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
